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We have modified the pCL retroviral system by the insertion of a p53-responsive element, called PG, in the U3 region of the 3V-LTR,
either in addition to or in place of the native negative control region/enhancer sequence. We show here that either endogenous or exogenous
wild-type p53 may be used to drive expression from the pCLPG system in transduced cells. Upon genotoxic induction of endogenous p53,
pCLPG expression surpassed that of the parental, nonmodified virus, specifically when the native promoter was removed and substituted by
the p53-responsive element. We propose that the novel pCLPG system will prove to be a valuable tool whether used as a reporter system of
p53 function or as an in vitro and in vivo gene transfer vehicle.
D 2004 Elsevier Inc. All rights reserved.Keywords: p53; Retrovirus; pCL; LTR; Transcriptional regulation; Chemotherapeutic drugsIntroduction
For increased efficacy and safety, tight transcriptional
control is a highly desirable feature in a viral gene transfer
vector. We have chosen to employ wild-type p53 as a
transcriptional activator of retroviral expression because
p53 activity is inducible and, in the active state, is a robust
transcription factor (Ko and Prives, 1996). The activity of
the wild-type p53 protein includes transcriptional activation
of key cell-cycle and pro-apoptotic control genes, for
example, p21Waf1 (el-Deiry et al., 1993) and the p53
antagonist, mdm2 (Barak et al., 1993; Haupt et al., 1997).
Transcriptional activation by p53 is mediated via direct
binding to a known DNA motif present in the regulatory
elements of target genes (el-Deiry et al., 1993; Funk et al.,
1992). P53 also suppresses expression from a variety of
promoters, including anti-apoptotic control genes (Miya-
shita et al., 1994a, 1994b), the multidrug resistance gene
(Chin et al., 1992; Strauss et al., 1995), and some viral
promoters, including the LTRs of RSV, HIV-I, and HTLV-10042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: bstrauss@usp.br (B.E. Strauss).(Subler et al., 1992). One of the first p53-responsive
elements to be identified was isolated from the ribosomal
gene cluster (RGC) (Kern et al., 1991). In the PG13-CAT
reporter construct, 13 copies of the RGC element were
joined to a minimal promoter and the chloramphenicol
acetyltransferase (CAT) cDNA, resulting in a highly sensi-
tive p53-responsive regulatory unit (Kern et al., 1992). In
this study, we have altered retroviral expression by inserting
the PG element into the U3 region of the 3V-LTR of the
Moloney Murine Leukemia Virus-based (MoMLV) pCL
retrovirus with the hope of gaining high-level expression
driven by p53 in infected cells. This method was preferred
over the insertion of p53-responsive promoters, such as for
the p21Waf1 gene, because these promoters may also act in
a p53-independent fashion (Michieli et al., 1994; Seoane et
al., 2002). We present here cell culture-based assays to
establish the function of the newly constructed pCLPG
retroviral gene transfer system.Results
Construction and production of modified pCL virus
In order to generate retroviruses with p53-driven expres-
sion, the PG element was isolated (Kern et al., 1992) and
inserted in the U3 region of the 3V-LTR of the MoMLV-
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native enhancer elements (pCLPG+, pCLPG, Fig. 1) where
the PG element was placed in either the sense (+) or antisense
() orientation. Alternatively, the enhancer and negativeFig. 1. Maps of the pCLPG system and p53-dependent expression after acute inf
vectors. (A) The original MoMLV-derived pCL system (Naviaux et al., 1996) was
from the PG13-CAT reporter construct (Kern et al., 1992). The sequence is referr
detail of the CMV-R-U5 fusion at the 5V-LTR, the presence of the packaging signa
neomycin resistance gene (NeoR), and the 3V-LTR with the negative control regio
For the pCLPG vectors, the PG element was inserted in the XbaI site, maintaining
with the PG element in both orientations (pCLPG+ and pCLPG). For the pCL
replacing the N and E sequences, as detailed in the diagram, and clones were isolat
The native CAT and TATA elements were maintained in all of the modified constr
the multiple cloning sequence of each of the four modified vectors as well as the no
as the pCLPGCAT series (pCL, pCLCAT, pCLPG+CAT, pCLPGCAT, pCLPG+D
p53 inactivated by adenovirus E1B protein) was infected at an MOI of 0.6 with
figure) in a 6-cm dish, the day the infected cells were equally divided between th
CMV vector (V), or the CMV vector encoding wild-type p53 (p53wt) or mut
transfected cells were harvested for CAT assays. Each assay was performed wit
standard deviation of three independent experiments.control regions were deleted and replaced by the PG element
(pCLPG+DU3, pCLPGDU3, Fig. 1) where the PG element
was placed in either the sense (+) or antisense () orienta-
tion. These four arrangements were tested with the intentionection of the pCLPG system followed by transfection with p53 expression
modified by the insertion of 13 copies of a p53-responsive element derived
ed to here as the PG element. The nonmodified vector, pCL, is shown with
l, the multiple cloning site, the SV40 promoter that drives expression of the
n (N), enhancer elements (E), and NheI and XbaI restriction sites indicated.
the N and E sequences, as detailed in the diagram, and clones were isolated
PGDU3 vectors, the PG element was inserted in the NheI and XbaI sites,
ed with the PG element in both orientations (pCLPG+DU3, pCLPGDU3).
ucts. The chloramphenicol acetyltransferase (CAT) cDNAwas inserted into
nmodified parental construct. For simplicity, the vectors are referred to here
U3CAT, pCLPGDU3CAT). (B) The 293 cell line (endogenous wild-type
each one of the six viruses in the pCLPGCAT series (as indicated in the
ree fresh 6-cm dishes, transfected the following day with 5 Ag of an empty
ant p53 (p53mut). After an additional 24-h incubation, the infected and
h 30 Ag of protein lysate for 60 min. The histogram depicts the mean F
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The cDNA for chloramphenicol acetyltransferase (CAT)
was inserted in the modified vectors as well as the non-
modified pCL vector to serve as a control. A similar range
of viral titers, as determined by G418 resistance in an end-
point dilution assay, was obtained for the parental vectors,
pCL and pCLCAT (3  106, 2  105, respectively), and
the modified pCLPG+CAT, pCLPGCAT, pCLPGD+CAT,
or pCLPGDCAT constructs (1  105, 6  105, 2  105,
8  106 cfu/ml, respectively). Assessment of replication
competent virus showed no additional generation of re-
combinant virus for the PG-modified vectors as compared
to the parental, nonmodified vector (data not shown).
These results indicate that the modifications were not
harmful to the processes of virus production, infection,
or selection.
Expression of the pCLPG system in an acute infection assay
To begin testing of the pCLPG system, 293 cells were
infected at an equal multiplicity of infection with pCL,
pCLCAT, pCLPG+CAT, pCLPGCAT, pCLPG+DU3CAT,
or pCLPGDU3CAT (for simplicity referred to as the
pCLPGCAT series), replated the following day, and then
transfected with CMV-driven expression vectors for wild-
type or mutant p53. As seen in Fig. 1B, the introduction of
the p53 expression vectors had only a minimal effect on the
expression of the nonmodified pCLCAT virus. In contrast,
all PG-modified viruses exhibited an increase in viral
expression in the presence of wild-type p53, but not in the
presence of the empty or mutant p53 vectors. This indicates
that the pCLPG system is indeed activated by p53 in acutely
infected cells. The expression observed from the
pCLPGDU3CAT vector in the presence of exogenous
p53 was greater than that of the nonmodified pCLCAT
virus.
Assessment of basal expression in a variety of cell types
The expression of the pCLPG system was consistent with
the phenotype of the endogenous p53 in several cell lines.
The human lung carcinoma cell line H358 (p53-null), the
human glioblastoma cell lines U251 (mutant p53) and U87
(wild-type p53), as well as the human osteosarcoma Saos-2
(p53/) cell line were each infected with the pCLPGCAT
series (MOI < 1), selected for G418 resistance, and assayed
for viral expression. As seen in Fig. 2, the expression from
the parental pCL virus was quite variable and appeared to be
quite low in Saos-2 cells, yet was greater in the other lines
when reactions were performed under similar conditions.
The lack of endogenous p53 in the H358 cells corresponded
with negligible expression from the pCLPG system. In the
U251 cells, the activity of the pCLPG system was quite
reduced as compared to the parental virus, presumably
because of the lack of functional p53. The endogenous,
wild-type p53 in the U87 cells appeared to activate the PG-modified viruses, though expression was less than that from
the parental virus. Expression from the pCLPG+CAT,
pCLPGCAT, and pCLPG+DU3CAT viruses was barely
detectable in the p53-null Saos-2 cells, yet leaky expression
from the pCLPGDU3CAT virus was observed. These
assays indicate that the basal expression from the pCLPG
system is quite low in the absence of p53.
Expression from the pCLPG system in response to a
temperature-sensitive mutant of p53
Next, we wished to compare the basal and induced
expression from the pCLPG system when p53 was provided
stably by an expression vector. A temperature-sensitive
mutant of murine p53 (Michalovitz et al., 1990) was
introduced into the Saos-2 (p53/) human osteosarcoma
cell line previously transduced with the pCLPGCAT series
of viruses, as described above, via a second retroviral
infection using the pBabep53(Val135)puro retrovirus. These
cells were then selected for puromycin resistance with
continued presence of G418 in the culture media. Batch-
selected cells were then cultured at either 37 jC, where p53
adopts a mutant conformation and is unable to activate
transcription, or at 32 jC, where p53 assumes wild-type
conformation and activity. Cells were collected after 5 days
of temperature conditioning and analyzed for reporter gene
activity.
Measurement of viral expression with the CAT reporter
gene in the temperature-sensitive system revealed p53-
specific expression that surpassed the level of expression
seen in the parental virus (Figs. 2B, C). In the absence of
p53, negligible background expression was observed from
the pCLPG+CAT or pCLPGCAT vectors, yet leaky ex-
pression was evident for the pCLPGDU3CAT vector at
both 32 and 37 jC, and the pCLPG+DU3CAT vector
revealed background expression only at 32 jC. The non-
specific band present in these assays migrated differently
than either the mono- or diacetylated forms of chloram-
phenicol, and was discounted from the densitometric anal-
yses. In the presence of mutant p53, at 37 jC, the Saos-
pCLPGCAT/p53(Val135) series of cell lines exhibited only
background expression, equal to that in the complete ab-
sence of p53. Strikingly, the PG-modified vectors were
induced at 32 jC in the presence of wild-type p53 activity.
Expression from the pCLPGDU3CAT vector was mea-
sured to be nearly sevenfold greater than the nonmodified
parental pCLCAT vector.
Endogenous p53 can be induced to drive expression of the
pCLPG system
To demonstrate the p53-inducible nature of the pCLPG
system, NIH3T3 cells (p53+/+) were infected with the
pCLPGCAT series of viruses (MOI < 1) and selected for
G418 resistance. Cells were treated with 100 ng/ml doxo-
rubicin, a genotoxic and p53-inducing chemotherapeutic
Fig. 2. A comparison of the pCLPG system in four different cell lines. (A) The H358 (human lung carcinoma, p53/), U251 (human glioblastoma, mutant
p53), and U87 (human glioblastoma, wild-type p53) cell lines were infected with the pCLPGCAT series of vectors, selected for G418 resistance and cell lysates
analyzed by CAT assays. For these assays, an equal amount of protein was applied for each cell line (2–30 Ag), however the quantity for each line of origin was
adjusted to maintain assays within the linear range. The histograms show the mean percent of the chloramphenicol substrate converted to the acetylated form in
at least three independent experiments. Lane designations described below. (B) Saos-2 cells (p53/ human osteosarcoma) infected with the pCLPGCAT
series of virus and selected for G418 resistance were reinfected with the pBabep53(135)puro virus and selected for puromycin resistance while in the continued
presence of G418, resulting in the generation of the Saos-pCLPGCAT and Saos-pCLPGCAT/p53(135) series of cell lines. CAT activity measured after
induction of the pCLPG system by this temperature-sensitive mutant of p53. The Saos-pCLPGCAT series of cell lines was incubated at 32 jC (white bars) or
37 jC (striped bars) and the Saos-pCLPGCAT/p53(135) series of cell lines was incubated at 32 jC (black bars) or 37 jC (stippled bars) for 120 h before
harvesting of cells and analysis of CAT activity. The histogram represents the mean percentage of conversion of chloramphenicol to the acetylated form, as
determined by densitometric analysis of the autoradiographs, from two independent experiments. Lane designations described below. (C) Representative
examples of the CAT assays described in panel B. Note the presence of a nonspecific background band; this band was discounted from the densitometric
measurements. For (A), (B), and (C), lanes were 1, pCL; 2, pCLCAT; 3, pCLPG+CAT; 4, pCLPGCAT; 5, pCLPG+DU3CAT; and 6, pCLPGDU3CAT.
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expression. As seen in Fig. 3A, expression from the
pCLCAT parental virus was readily detectable in the ab-
sence of drug treatment, but decreased slightly with the
addition of doxorubicin. In contrast, the expression of the
reporter gene from each of the PG-modified viruses in-
creased with drug treatment, as much as threefold for
pCLPG+DU3CAT. Notably, when in the presence of doxo-
rubicin, expression from the pCLPGDU3CAT virus was
nearly twofold greater than that of the nonmodified
pCLCAT virus. The pCLPGDU3 arrangement conferred
a p53-inducible expression that surpassed that of the paren-
tal, nonmodified virus, corroborating the results seen in
Figs. 1 and 2.
To explore the p53-responsive nature of the pCLPG
system at the transcriptional level, a Northern blot was
performed using total RNA isolated from the NIH3T3 cellsinfected with the pCLPGCAT series, with and without
doxorubicin treatment. As seen in Fig. 3B, expression from
the pCLCAT vector was diminished slightly by drug treat-
ment as indicated by detection of the viral transcript with
either the CAT or NeoR cDNA probes. In contrast, all PG-
modified vectors were induced by drug treatment.
To relate the above results with the physiologic response
of the endogenous p53 to drug treatment, Western blots and
RT-PCR were performed using either protein lysates or total
RNA, respectively, of the NIH3T3-pCLPGCAT series of
cell lines. As shown in the Western blot (Fig. 3C), the level
of endogenous p53 protein is quite low in the absence of
drug treatment, yet exposure to doxorubicin induced the
stability of the p53 protein. The stabilized p53 protein is
known to activate the expression of a variety of genes,
including p21Waf1. Indeed, expression of this p53-target
gene was activated in response to drug treatment, in agree-
Fig. 3. Activation of endogenous p53 by a genotoxic drug induces expression from the pCLPG system. NIH3T3 cells (wild-type p53) were infected (MOI < 1)
with the pCLPGCAT series of viruses and selected for G418 resistance. For these assays, 0 or 100 ng/ml doxorubicin was added and the cells incubated 24
h before harvesting for CAT assays, Northern or Western blots. (A) CAT assay were performed with an equal quantity of protein from each lysate, 5 Ag, and
incubated for 30 min at 37 jC. The histogram represents the mean F standard deviation of densitometric analyses of two independent experiments. Lane
designations described below. (B) Northern blot analysis of total RNA probed sequentially with the CAT, NeoR, or h-actin cDNAs. A single membrane was
used for this experiment, exposures made to phosphor imaging screen, and stripped between probes. Note the altered migration of transcripts hybridizing with
CATor NeoR cDNAs that represents the expected alteration in transcript length due to the inserted cDNA and alteration to the LTR. For (A) and (B), lanes were
1, pCL; 2, pCLCAT; 3, pCLPG+CAT; 4, pCLPGCAT; 5, pCLPG+DU3CAT; and 6, pCLPGDU3CAT. (C) Western blot analysis of endogenous p53 and its
transcriptional target, p21Waf1, after treatment with doxorubicin. For the Western blot, an immunoprecipitation was first performed using the indicated
antibody, then the complex analyzed by Western blot using the same antibody. This procedure served to concentrate the target protein. The same lysate was
subjected to the immunoprecipitation-Western analysis sequentially with each antibody. Detection of h-actin protein serves as a control for sample handling and
loading. (D) Semiquantitative RT-PCR for the analysis of the transcripts of p53 and its target genes p21Waf1 and mdm2 with or without drug treatment. For the
RT-PCR, negative controls (water in PCR, lane 1, water in RT, lane 2), h-actin (lanes 3, 4), p53 (lanes 5, 6), p21Waf1 (lanes 7, 8), and mdm2 (lanes 9, 10) were
amplified as described in the Materials and methods. The result from NIH3T3-pCL is shown here; the remaining lines in the NIH3T3-pCLPGCAT series
yielded the same result and, therefore, are not shown.
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RT-PCR assay (Fig. 3D) confirmed this widely-known
mechanism, showing that p53 RNA was not elevated in
response to drug treatment, yet the p53-target genes
p21Waf1 and mdm2 were. Taken together, these results
indicate that the drug treatment induced p53 activity which,
in turn, induced expression from the pCLPG system.Discussion
We have constructed the pCLPG retroviral gene transfer
system whose expression is driven by p53. In the pCLPG-
infected cell, LTR-driven expression depends principally on
wild-type p53 activity. This was shown by the introduction
of p53 in infected cells as well as by the induction of endo-
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system was tested in a variety of different cell types after
infection and selection, revealing variable activity of the
nonmodified LTR as well as expression driven by the PG
modified LTR in a p53-associated manner. Strikingly, ex-
pression from the pCLPG system could surpass that of the
parental, nonmodified virus by up to sevenfold.
We propose that the new virus system will prove to be a
valuable tool for either gene transfer or reporter assays. For
studies of gene transfer, the replacement of the negative
control region and enhancer element may prove beneficial
for long-term expression in vivo (Challita et al., 1995). The
responsiveness of the pCLPG system to p53 may be utilized
to restrict expression to p53-positive cells and further induce
expression when those cells are treated with a genotoxic
drug, as was clearly demonstrated with the pCLPGDU3
vector whose expression surpassed that of the parental pCL
virus. Retroviral transduction of hematopoietic stem cells
with MDR1 (Chin et al., 1993) has been extensively studied
and attempted clinically, but with disappointing results
because of both the lack of expression of the transgene
and poor transduction efficiency (Hanania et al., 1996;
Hesdorffer et al., 1998). In the case of pCLPG-mediated
delivery of the MDR1 cDNA, a drug used for chemotherapy
and which activates p53 should, in turn, activate MDR1
expression in the hematopoietic cells, protecting and select-
ing them for continued proliferation.
The pCLPG system may be utilized as a reporter con-
struct, especially the pCLPG+ vector that yielded the lowed
background expression of the LTR modifications tested.
Applied to monitor p53 activity in vivo, the target tissue
may be infected by the pCLPG virus system, or ex vivo,
because cells may be removed, infected, and then implanted
in a recipient. The ex vivo approach may be especially
interesting to monitor p53 activity in the hematopoietic
system during reconstitution, upon genotoxic stress, or upon
immunologic activation.Materials and methods
Parental vectors
The MoMLV-based pCL and pCL-amphotropic packag-
ing vectors are described in Naviaux et al. (1996).
Construction of the pCLPG system
The PG element (13 copies of the p53 responsive ele-
ment) (Kern et al., 1992) was gel isolated from the PG13-
CAT construct following digestion with HindIII and SmaI
and a fill-in reaction to render the HindIII overhang
‘‘blunt’’. The pCL retroviral vector (Fig. 1) was cut with
XbaI and the overhangs were filled in to produce blunt ends.
The PG element was then ligated into the pCL vector.
Clones were isolated where the PG element was situatedin the positive orientation (pCLPG+) or in the negative
orientation (pCLPG) as shown in Fig. 1.
Alternatively, the pCL vector was cut with NheI and
XbaI, treated with T4 DNA polymerase to create blunt ends,
and the 7.3 kb vector fragment was gel isolated before
insertion of the PG element. The resulting clones have the
endogenous pCL enhancer elements deleted and replaced
with the PG element. Clones were isolated where the PG
element was situated in the positive orientation (pCLPG+
DU3) or in the negative orientation (pCLPGDU3) as
shown in Fig. 1.
Construction of the pCLPGCAT series
The CAT cDNA was isolated as an 800 bp HindIII
fragment from the pBS-IRES-CAT vector (Patricia Le´o,
University of Sa˜o Paulo, Sa˜o Paulo, Brazil, derived from
the pLZIC2 vector, Ghattas et al., 1991, kindly provided by
John Majors, Washington University, St. Louis, MO, USA)
and inserted into theHindIII site of pBluescript to create pBS-
CAT. The CAT cDNAwas then excised as an 800 bp BamHI
fragment and inserted into the BamHI site of pCL, pCLPG+,
pCLPG, pCLPG+DU3, and pCLPGDU3 to create the
pCLCAT, pCLPG+CAT, pCLPGCAT, pCLPG+DU3CAT,
and pCLPGDU3CAT vectors.
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell
line 293T (DuBridge et al., 1987), the p53-null, human lung
carcinoma cell line H358 (ATCC: CRL-5807), the p53-null,
human osteosarcoma cell line Saos-2 (ATCC: HTB-85), the
mouse fibroblast NIH3T3 (ATCC: CCL-163), the human
glioblastoma cell lines U87 (ATCC HTB-14), and U251
were maintained in DMEM (Gibco-BRL, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (FBS,
HyClone, Logan, UT, USA), 100 Ag/ml gentamycin, 50 Ag/
ml ampicillin, and 2.5 Ag/ml fungizone, at 37 jC, in a
humidified atmosphere of 5% CO2. H358, Saos-2, NIHT3,
U87, and U251 cells were infected (MOI < 1) with the pCL
or pCLPGCAT series of viruses and selected with 800 Ag/ml
G418 (Invitrogen Life Technologies, Carlsbad, CA, USA),
then maintained as batch-selected cells with 400 Ag/ml
G418 in DMEM, creating the five pCLPGCAT series of
cell lines. For the Saos-pCLPGCAT series of cell lines, a
second infection was performed with the pBabep53(135)-
puro virus supernatant (see following sections) and cells
were selected with 0.5 Ag/ml puromycin (Sigma, USA) in
the presence of 400 Ag/ml G418 in complete medium,
creating the Saos-pCLPGCAT/p53(135) series of cell lines.
Virus production, titration, and RCR assay
To produce virus-containing supernatant, the indicated
viral and amphotropic packaging vectors were transfected in
the 293 cells as described (Bajgelman et al., 2003; Naviaux
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supernatant was collected, centrifuged for 5 min, 1000 rpm,
then the supernatant removed and stored at 70 jC. The
pBabep53(Val135)puro retroviral vector was kindly provid-
ed by Moshe Oren, Weizmann Institute, Rehovot, Israel.
This vector encodes the mouse temperature-sensitive allele
of p53 (Michalovitz et al., 1990) as well as the puromycin
resistance gene. Viral supernatant was produced as per the
pCL-based vectors co-transfecting the pCL-Ampho packag-
ing construct along with pBabep53(Val135)puro. Titration,
performed by end-point dilution and selection for G418
resistance, and the assay for replication competent retrovirus
(RCR) were performed as described previously (Bajgelman
et al., 2003).
CAT assays
CAT assays (Gorman et al., 1982) were performed using
5–150 Ag of lysate, 1 Al of 14C-chloramphenicol (CFA515,
Amersham-Pharmacia), 2 Al of 10 mg/ml acetyl Co-A, and
250 mM Tris, pH 7.8, to a final volume of 125 Al. The
reactions were incubated at 37 jC for 1–2 h before extrac-
tion with 500 Al of ethyl acetate. The organic layer was
transferred to a fresh tube and dried under vacuum. The
pellet was then resuspended in 25 Al of ethyl acetate and
applied to a silica gel thin-layer chromatography plate. The
plate was then placed in a TLC chamber equilibrated with
100 ml of 93:7 chloroform and methanol, respectively, and
migration of the solvent front was allowed to proceed until
reaching the end of the plate. The plate was then removed,
dried, and exposed to X-ray film overnight. Quantification
was performed by densitometry.
Northern blot for the detection of p53, neomycin-resistance
gene, and b-actin
For the NIH3T3-pCLPGCAT series, one 10-cm dish of
each cell line were treated overnight with complete medium,
and 100 ng/ml of doxorubicin and an additional dish was
incubated in parallel, with no drug treatment, and all lines
were maintained at 37 jC before purification of total RNA
using Trizol reagent (Invitrogen Life Technologies) accord-
ing to the manufacturer’s instructions. The RNA, 20 Ag of
each sample, was separated by denaturing gel electropho-
resis, transferred to HyBond nylon membrane (Amersham
Biosciences), and subjected to UV-cross-linking. The mem-
brane was then probed using 32P-dCTP-labeled cDNAs forTable 1
Oligonucleotide primers utilized in semiquantitative RT-PCR assays
Target gene Forward primer Reverse prim
h-Actin 5V-gcaagagaggtatcctgacc-3V 5V-ctctttgatgtc
p53 5V-ggagtcacagtcggatatca-3V 5V-accagctggc
p21 5V-actttgacttcgtcacggag-3V 5V-aagaccaatc
mdm2 5V-ggccaatgtgcaataccaac-3V 5V-ggactccaaaCAT (800 bp BamHI fragment recovered from pCLCAT),
h-actin (2.0 kb fragment provided by Rui Curi, ICB-USP),
and the neomycin resistance gene (800 bp HindIII–NaeI
fragment recovered from pCL) using Rapid-Hyb solution
and protocol (Amersham Biosciences). The membrane was
stripped by boiling in 0.1 SSC/0.1% SDS between each
probe and after exposure to phosphor imaging screen.
Western blot for the detection of p53, p21Waf1 and b-actin
Western blots for the NIH3T3-pCLPGCAT series were
performed, where a sub-confluent 10-cm dish of each cell
line was treated overnight with complete medium and 100
ng/ml of doxorubicin and an additional dish incubated in
parallel, with no drug treatment, and all lines were main-
tained at 37 jC. The cells were lysed in 1 ml of lysis buffer
(1 PBS, 1% NP-40, 0.1% SDS, 200 U/ml aprotinin, 0.5
mM PMSF, and 0.1 mM EDTA). An immunoprecipitation
was performed with a p53-specific antibody (PAb 421,
Oncogene Research Products, USA) and the complex was
separated by SDS-PAGE and detected by Western blot. The
same lysate was then sequentially analyzed with p21Waf1
(Santa Cruz Biotechnologies, CA, USA) and then h-actin-
specific (Sigma-Aldrich, St. Louis, MO, USA) antibodies
by the same immunoprecipitation-Western procedure.
Semiquantitative RT-PCR
For the NIH3T3-pCLPGCAT series of cell lines, a sub-
confluent 10-cm dish of each cell line was treated overnight
with complete medium and 100 ng/ml of doxorubicin and
an additional dish incubated in parallel, with no drug
treatment, and all lines were maintained at 37 jC. Total
RNA was isolated with Trizol reagent (Invitrogen Life
Technologies) and resuspended in DEPC-treated water.
Equal amounts of total RNA were used as the template in
reverse transcriptase reactions (2 Ag total RNA, 250 ng
random hexamers, 1 Al of 10 mM dNTPs, DEPC-treated
water to 12 Al, then heated before the addition of 4 Al 5
buffer, 2 Al of 0.1 M DTT, 200 units MMLV reverse
transcriptase [Invitrogen Life Technologies], incubated 37
jC for 60 min). The RT reactions were diluted 1:1 with
water, then 1 Al used in each PCR reaction (50 pmol each
primer, 1 Al 10 mM dNTPs, 1 Al 50 mM MgCl2, 2.5 Al 10
buffer, 2.5 units Platinum Taq [Invitrogen Life Technolo-
gies] and water to 25 Al) and cycled as follows: 95 jC, 3
min, 25 cycles of 95 jC, 1 min, 57 jC, 1 min, 72 jC, 1 min,er Derived from
GeneBank
Expected amplicon
(base pairs)
acgcacga-3V M12481 464
agaatagctt-3V NM011640 399
tgcgcttgga-3V AF457188 314
cacatctcct-3V X58876 260
B.E. Strauss, E. Costanzi-Strauss / Virology 321 (2004) 165–172172followed by a 5-min incubation at 72 jC. The oligonucle-
otide primers, presented in Table 1, were based on mouse
gene sequences and were designed to specifically amplify
cDNA. The reactions were separated by electrophoresis in
1.3% agarose and photographed and analyzed with an
EagleEye Imaging system (Stratagene, La Jolla, CA, USA).Acknowledgments
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